Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer

An association between over-expression of proto-oncogene Her-2/neu and resistance to tamoxifen in estrogen receptor (ER) positive, primary and metastatic breast cancer has been suggested. HR+/Her-2/neu+ patients have a poor response to endocrine therapy, making this group a matter of debate. The pre...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of medical research (New Delhi, India : 1994) India : 1994), 2011-01, Vol.133 (1), p.70-75
Main Authors: James, Rani, Thriveni, K, Krishnamoorthy, Lakshmi, Deshmane, Vijayalaxmi, Bapsy, P P, Ramaswamy, Girija
Format: Article
Language:English
Subjects:
Adjuvant treatment
Adult
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer
Care and treatment
Chemotherapy, Adjuvant
Combined Modality Therapy
Diagnosis
Drug Resistance, Neoplasm
Drug therapy
Estrogen Antagonists - therapeutic use
Female
Gene Expression Regulation, Neoplastic
Genetic aspects
Health aspects
Hormone therapy
Humans
Middle Aged
Original
Patient outcomes
Properties
Prospective Studies
Receptor, ErbB-2 - blood
Receptor, ErbB-2 - genetics
Tamoxifen
Tamoxifen - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An association between over-expression of proto-oncogene Her-2/neu and resistance to tamoxifen in estrogen receptor (ER) positive, primary and metastatic breast cancer has been suggested. HR+/Her-2/neu+ patients have a poor response to endocrine therapy, making this group a matter of debate. The present study was carried out to examine whether Her-2/neu expression in breast cancer patients predicted tamoxifen effectiveness. An enzyme-linked immunosorbent assay (ELISA) specific for the extracellular domain of the Her-2/neu oncoprotein product was used to detect serum Her-2/neu levels in 207 patients with histological confirmed breast cancer. Tissue Her-2 /neu expression was studied in 100 breast cancer patients by immunohistochemistry (IHC) and compared with serum Her-2/neu levels by ELISA. Among 207 histologically confirmed breast cancer patients, 53 were serum Her-2/neu positive. Patients who were treated with surgery, chemotherapy, and radiotherapy showed significantly (P
ISSN:0971-5916